Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CNTY
CNTY logo

CNTY Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Century Casinos Inc (CNTY) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.480
1 Day change
0.68%
52 Week Range
2.850
Analysis Updated At
2026/04/17
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Century Casinos Inc (CNTY) is not a strong buy for a beginner, long-term investor at this time. The lack of positive financial performance, weak growth outlook, and absence of significant trading or news catalysts suggest holding off on investment until clearer opportunities arise.

Technical Analysis

The MACD is slightly positive but contracting, RSI is neutral at 53.53, and moving averages are converging, indicating no strong trend. The stock is trading near its pivot point of 1.471, with resistance at 1.524 and support at 1.417.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
8
Buy
5

Positive Catalysts

  • Analyst Piper Sandler raised the price target to $4 from $2, citing plans to submit an IND for CNTY-813 this year and sufficient cash to fund operations into Q1 2029.

Neutral/Negative Catalysts

  • No recent news or significant trading trends from hedge funds, insiders, or Congress. The stock has a low probability of significant short-term gains.

Financial Performance

In Q4 2025, revenue grew marginally by 0.16% YoY to $137.99M. However, net income dropped significantly to -$17.95M, and EPS fell to -0.61. Gross margin improved slightly to 34.57%, up 2.01% YoY.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Piper Sandler maintains an Overweight rating and raised the price target to $4, highlighting long-term potential tied to CNTY-813 development. However, initial data is not expected until 2027, limiting near-term impact.

Wall Street analysts forecast CNTY stock price to rise
2 Analyst Rating
Wall Street analysts forecast CNTY stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.440
sliders
Low
4
Averages
4
High
4
Current: 1.440
sliders
Low
4
Averages
4
High
4
Piper Sandler
NULL
to
Overweight
upgrade
$2 -> $4
AI Analysis
2026-01-20
Reason
Piper Sandler
Price Target
$2 -> $4
AI Analysis
2026-01-20
upgrade
NULL
to
Overweight
Reason
Piper Sandler raised the firm's price target on Century Therapeutics to $4 from $2 and keeps an Overweight rating on the shares. The firm notes Century plans to submit an IND for CNTY-813 this year and report initial data in 2027. Piper estimates Century now hold pro forma cash of about $267M to fund operations into Q1 2029.
Clear Street
Bill Maughan
Buy
downgrade
$8
2026-01-08
Reason
Clear Street
Bill Maughan
Price Target
$8
2026-01-08
downgrade
Buy
Reason
Clear Street analyst Bill Maughan lowered the firm's price target on Century Therapeutics to $6.60 from $8 and keeps a Buy rating on the shares. The private placement brings the runway out to 1Q29, allowing for development of a fuller picture of the true potential of lead asset CNTY-813 before needing additional capital, the analyst tells investors in a research note. The firm added that it is reducing its price target on dilution from the raise, offset by increased pipeline likelihood of success and peak sales.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CNTY
Unlock Now

People Also Watch